This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, K. Articles by Yoshimatsu, K. Search for Related Content PubMed PubMed Citation Articles by Nakamura, K. Articles by Yoshimatsu, K.

Tsukuba Research Laboratories, Eisai Co. Ltd., Ibaraki 300-2635, Japan

DNA topoisomerase II has been shown to be an important therapeutic target in cancer chemotherapy. Here, we describe studies on the antitumor activity of a novel topoisomerase II inhibitor, ER-37328 [12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c]pyrimido[5,6,1-jk]carbazole-4,6,10(5H,11H)-trione hydrochloride]. ER-37328 inhibited topoisomerase II activity at 10 times lower concentration than etoposide in relaxation assay and induced double-strand DNA cleavage within 1 h in murine leukemia P388 cells, in a bell-shaped manner with respect to drug concentration. The maximum amount of DNA cleavage was obtained at 2 µM. Like etoposide, ER-37328 (2 µM) induced topoisomerase II-DNA cross-linking in P388 cells. A spectroscopic study of ER-37328 mixed with DNA demonstrated that ER-37328 has apparent binding activity to DNA. ER-37328 showed potent growth-inhibitory activity against a panel of 21 human cancer cell lines [mean (50% growth-inhibitory concentration) GI₅₀ = 59 nM]. COMPARE analysis according to the National Cancer Institute screening protocol showed that the pattern of the growth-inhibitory effect of ER-37328 was similar to that of etoposide, but different from that of doxorubicin. Studies on etoposide-, amsacrine [4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA)]-, and camptothecin-resistant P388 cell lines showed that: (a) etoposide- and m-AMSA-resistant P388 cell lines were partially resistant to ER-37328 compared with the parental cell line; and (b) a camptothecin-resistant cell line showed no cross-resistance to ER-37328. In addition, ER-37328 overcame P-glycoprotein-mediated resistance. In vivo, ER-37328 produced potent tumor regression of Colon 38 carcinoma inoculated s.c., and its activity was superior to that of etoposide or doxorubicin. These results indicate that ER-37328 inhibits topoisomerase II activity through the formation of topoisomerase II-DNA cleavable complex and has potent antitumor activity both in vitro and in vivo.

This article has been cited by other articles:

				A. Pourpak, T. H. Landowski, and R. T. Dorr Ethonafide-Induced Cytotoxicity Is Mediated by Topoisomerase II Inhibition in Prostate Cancer Cells J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1109 - 1117. [Abstract] [Full Text] [PDF]

				A. Maralhas, A. Monteiro, C. Martins, M. Kranendonk, A. Laires, J. Rueff, and A. S. Rodrigues Genotoxicity and endoreduplication inducing activity of the food flavouring eugenol Mutagenesis, May 1, 2006; 21(3): 199 - 204. [Abstract] [Full Text] [PDF]

				K. Nakamura, T. Taniguchi, Y. Funahashi, and K. Yoshimatsu Effects of ER-37328 on Primary Tumor, Liver Metastasis, and Life Span in a Murine Colon 38 Orthotopic Transplantation Model Mol. Cancer Ther., January 1, 2003; 2(1): 59 - 64. [Abstract] [Full Text] [PDF]